News

Tesla Q2 Earnings Preview: Robotaxis, Disappointing EV Sales and Politics in Focus ahead of Earnings Call

Posted on: Jul 18 2025

Tesla Q2 Earnings Preview: Robotaxis, Disappointing EV Sales and Politics in Focus ahead of Earnings Call

Key Points

  • Tesla reports Q2 earnings on Wednesday, 23 July after the market close with the stock –15% lower YTD
  • Sales have slumped – revenues, margins and earnings are seen declining sharply
  • Investors pin hopes on earnings call with CEO Elon Musk for updates on robotaxis, new product launches and AI initiatives
  • Questions remain over loss of EV credits and Musk’s political aspirations

TL/DR: Q2 numbers are going to be bad on most fronts - the update from Elon Musk on robotaxis, new product timelines, AI initiatives will matter more for the stock.

Tesla is set to report a double-digit decline in revenue and earningsamid a slump in sales, fading EV market share, sterner competition and a brand left somewhat tarnished by CEO Elon Musk’s recent foray into politics. Loss of EV credit sales will be material and maybe not properly reflected in share price.

Overview

Revenues are seen declining more than 11% to $22.4 billion, with earnings per share down 23% to $0.40 after a very difficult year-to-date for the company as it battles brand tarnish, flailing sales in Europe, rising competition in China and ongoing doubts about its ability to roll out robotaxis.

The critical thing this quarter will be the comments from Elon Musk on the call. His latest foray into the political sphere unnerved investors who had thought he was fully dialled into the Tesla narrative once again following his departure from DOGE and acrimonious split with President Trump.

His commentary will be vital to sustaining the Tesla bull narrative. We'll be looking for detail on the company's new product launches and expansion plans, the latest on Full Self Driving (FSD) and the impact of the loss of EV credits. Meanwhile investors will be especially hungry for updates on the robotaxi rollout following the debut in Austin, Texas last month. This was deemed initially a success but questions over safety soon surfaced. 

Sales Are Down

First of all, the market is well positioned for a major decline in revenues due to the sales slump in Q2. Tesla delivered 384,122 cars (373,728 Model 3/Y and 10,394 other models) worldwide in the second quarter, a decline of 13.5% from the year-ago quarter. The second consecutive quarterly sales drop was also its biggest quarterly decline on record.  

For Q1 2025 revenue fell 9% year-on-year to $19.34 billion, automotive margins slid to 16.3% and EPS missed consensus by almost a third. Management responded by withdrawing its full-year 2025 growth outlook, blaming "evolving trade policies" and "uncertain macroeconomic conditions".

Whilst the decline in first quarter sales was attributed to the product mix as the company swung to the Model Y ramp, the same excuse won't wash this time.

Trade policy risks remain as the European Union may look at retaliatory tariffs on US-made cards, while China has also indicated it could increase levies on EVs. 

Politics has played a part with Musk’s support for right-wing parties in Europe apparently seeing consumers shy away. European sales fell 28% in May despite the wider EV market growth in the region.

Competition is fierce - Tesla’s market share in China has roughly halved from 10% to 5% in the last 5 years as the likes of BYD have caught the US brand. BYD has surpassed Tesla’s global market share.

EV credits

And Trump's "big, beautiful tax bill" signed in law during the quarter means the loss of EV tax credits, which has already led to temporary price cuts of up to $7,500 on Model 3 and Model Y vehicles, further pressuring embattled margins.

The Trump bill, which will cut about $2bn in EV tax credits for Tesla, ends penalties under the corporate average fuel economy (Cafe) standards for more polluting automakers, who buy billions of dollars of emissions credits from Tesla. Under the bill, Cafe fines are set at zero, negating the need for other automakers to purchase credits from Tesla, which relies heavily on the income stream.

In the first quarter, Tesla revenues from emissions credits rose 35 per cent to $595 million, surpassing the company’s overall $409 million of net income. Last year, Tesla generated $2.8 billion in revenue from selling regulatory credits worldwide, up from $1.8bn in 2023. In total this amounted to 39 per cent of its $7.1 billion annual net income.

Ending emissions credits may not have an immediate impact on Tesla’s bottom line since it has struck multi-year agreements with other automakers, and these could take years to wind down. Moreover, Tesla can still make money from selling credits overseas – recently striking a pooling arrangement with other automakers in the EU. But around three-quarters of emissions credits revenues are currently generated in the US, it’s thought. The loss of this income stream needs to be adequately addressed by Musk in the call.

Automotive Sales Guidance and Margins

Sales in Europe have collapsed and it is unclear how this is about to be turned around. Tesla management said they would provide full-year guidance in the upcoming Q2 update so this will be pivotal for the stock and has the potential to be a significant catalyst for the stock, albeit the Street has an estimated of between 1.35mn and 1.66mn deliveries this year - there is a wide range to be hit.

It's likely Tesla will report revenues from automotive sales down more than 6%, with margins down to 15%, three percentage below the same quarter a year ago.

Weighing onmargins is Tesla's huge operating expenses and capital expenditures. It is continuing at 2024's elevated spend levels to expand gigafactory output, ramp 4680 battery cell production, and improve its Supercharger network. Revenues from energy generation and storage are however seen rising to more than $3bn, a positive development. Tesla is also spending big on AI-related technologies and new product launches.

Robotaxis

One of the key things on the earnings call will be Musk’s position on the robotaxi rollout and state of FSD. Tesla launched robotaxis in Austin, Texas on 22 June with a very small number of Model Y vehicles. There were reports of some robotaxis violating traffic laws in Austin, such as brief lane drift, speeding near pedestrians caught on video. The National Highway Traffic Safety Administration is looking into it, and while it may not signify a long-term problem for the technology it does indicate that even with a relatively small and controlled debut Tesla is facing a mountain to scale this up without incurring more scrutiny and problems. It also underscores a sense of caution about Tesla’s Full Self Driving technology. The tech being trialled in Austin, FSD Unsupervised, is not currently on sale to general Tesla owners.

Politics

Finally, we will need to hear more on the politics. No doube Musk’s proximity to Trump hit hte brand in many quarters and his focus on DOGE meant he took his eye off Tesla, according to many shareholders. Renewed doubts about Musk’s focus on running Tesla hit the stock this month after he announced plans to launch a new political party, the America Party, to take on Republican and Democrat incumbency by focussing “on just 2 or 3 Senate seats and 8 to 10 House districts.”  Whilst Musk didn’t say anything about taking time off from Tesla, investors felt the move back into the political sphere would mean he becomes more distracted. Investors got what they wanted when Musk quit DOGE last quarter – they are worried about renewed political posturing. A key question for the earnings call is which Musk investors see – the one fully dialled in for Tesla or the one talking politics and the debt?

 

 

 

This content is marketing material and should not be regarded as investment advice. Trading financial instruments carries risks and historic performance is not a guarantee of future results. The instrument(s) referenced in this content may be issued by a partner, from whom Saxo receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.
Neil Wilson
Investor Content Strategist
Saxo Bank
Topics: Equities United Kingdom Highlighted articles UKMustRead UK Generic Disclaimer FR US Actualites et Analyses Trump Version 2 - Investors Volatility investor TagFeed En hurtig tanke
Getting paid to buy Novo Nordisk: earn income while waiting for a better price

Posted on: Jul 09 2025

Getting paid to buy Novo Nordisk: earn income while waiting for a better price

After a spectacular run-up through 2023 and early 2024, Novo Nordisk shares have cooled down. The stock, once the poster child of the GLP-1 obesity drug boom, now trades around USD 69—down sharply from its highs near USD 135. A recent combination of supply bottlenecks, executive changes, and a slightly more cautious outlook has added volatility to the share price. But for long-term investors who still believe in Novo’s story, that volatility opens a door.

What if you could get paid while waiting to buy the shares at a discount?

That’s exactly what a cash-secured put strategy offers.

A look at Novo’s journey—and the current pull-back

Over the last five years, Novo Nordisk has delivered stellar returns, fueled by global demand for its diabetes and weight-loss medications, particularly Ozempic and Wegovy. But every great growth story experiences pauses. As you can see in the chart below, the recent correction has brought the stock back to levels last seen in late 2023.

Five-year stock price chart of Novo Nordisk showing steady growth until late 2024, followed by a pull-back © Saxo

We’re using the U.S.-listed ADR version of Novo Nordisk (ticker: NVO) because options are not available on the Denmark-listed shares.

This retracement doesn’t necessarily mean the story is over—it may simply mean the valuation got ahead of itself. And if you’re a long-term investor who believes in the future of GLP-1 treatments, the current price may feel like an opportunity.

But instead of buying shares outright at  USD 69, there’s a more strategic approach.

Important note: The strategies and examples described are purely for educational purposes. They assist in shaping your thought process and should not be replicated or implemented without careful consideration. Every investor must conduct their own due diligence, considering their financial situation, risk tolerance, and investment objectives before making decisions. Remember, investing in the stock market carries risks, so make informed decisions.

What’s a cash-secured put, in plain English?

Imagine you’re willing to buy 100 Novo shares—but only if the price drops a little more, say to USD 64. Now imagine someone pays you  USD 170 today for that possibility. That’s a cash-secured put: you’re selling someone else the right to sell you shares at a set price, and in return, you’re paid a premium upfront.

To do this safely, you set aside the full amount needed to buy the shares (USD 6 400 in this case), so you’re covered if it happens. It’s called “cash-secured” because your obligation is fully backed by cash.

This strategy is particularly suitable for conservative investors. You either:

  • Earn income if the shares stay above your target price, or
  • Buy the stock you already wanted, but at a discount.

Let’s look at a real example.

The trade: selling the USD 64 put expiring August 8, 2025

As of today, with Novo Nordisk trading near USD 69, the August 8 put option with a USD 64 strike is trading around USD 1.70 per share. That means you can collect USD 170 in premium (since each contract represents 100 shares) for agreeing to buy the stock at USD 64 if it drops.

Option chain for Novo Nordisk showing the $64 strike put expiring August 8, 2025 with a bid-ask of 1.58–1.74 © Saxo

To execute this, you'd sell one put contract and set aside USD 6 400 in cash. That’s the maximum you’d need to buy the shares if assigned.

Now here’s the part that many investors love: if the share price stays above USD 64 through August 8, the put expires worthless—and you keep the USD 170 premium. On a cash commitment of USD 6 400, that’s a 2.7% return in just 32 days.

On an annualised basis, that works out to roughly 29%, assuming you could repeat this kind of trade every month (which, of course, isn’t guaranteed).

Strategy window showing a short put position on Novo Nordisk with a $64 strike and $170 premium, including risk-reward graph. © Saxo

This “get paid to wait” yield is the real power of cash-secured puts—especially when premiums are elevated, as they are now due to increased short-term volatility in the stock.

What can happen at expiration?

There are two possible outcomes—both acceptable, depending on your investment goals.

Scenario 1: Novo stays above USD 64 Your put expires worthless. You keep the $170 premium as pure income. Your €6 400 in cash was never used to buy shares, and you can now consider repeating the strategy for another month.

Scenario 2: Novo falls below USD 64 You’re assigned 100 shares at USD 64, which you already agreed to. But thanks to the USD 1.70 premium you received, your effective purchase price is USD 62.30—a further 10% discount from where the stock was trading just a few weeks ago. From here, you could simply hold the shares or start generating income with a covered call.

Risks to keep in mind

No investment strategy is without risk—even one that sounds this conservative.

The biggest risk here is that Novo drops well below USD 64 before expiration. If the stock falls to USD 55, for instance, you’d still be obligated to buy it at USD 64, meaning you'd have a paper loss on your new position. However, because you were paid USD 1.70 upfront, your break-even point is actually USD 62.30.

Another factor to be aware of: Novo Nordisk trades as an ADR on the NYSE (ticker: NVO), but its home listing is in Denmark. That means movements in the Danish krone (DKK) versus the US dollar can also influence the price. And like all pharma stocks, headlines about clinical trials, competition (such as Eli Lilly’s Zepbound), or regulatory changes can move the share price quickly.

Final thoughts

If you're a long-term investor looking to add Novo Nordisk to your portfolio, selling a cash-secured put at $64 offers a compelling way to do so—either collecting a ~2.7% yield in one month or buying the stock nearly 10% below the current price.

It’s a calm, measured approach in a market that’s been anything but.

Just remember: while cash-secured puts are straightforward, they still require a clear plan. Know how much capital you’re willing to commit, stick to high-quality names you’re happy to own, and never forget that your real return depends on both outcome and discipline.

Related articles/content             
Get paid to wait - how to earn income while preparing to buy Palantir shares There s another way to buy SAP - one that pays you How to get paid for your patience - Using cash-secured puts to invest in Intel How to turn your Intel shares into an income machine - even in a tough market Already own Logitech - or want to - There is a smarter way to invest either way How long-term investors can earn income or buy Alibaba at a discount with options Earning extra income and buying at a discount - Covered calls and cash-secured puts on Palantir How to earn extra Income from your Nestle shares - without taking on unnecessary risk How to use cash-secured puts to buy UBS stock - or earn income while you wait Learn how to generate income from ASML shares using MINI-options Learn how you can earn income or buy Bitcoin at a discount How a covered call on AMD generates extra income for long-term investors Learn how you can earn income or buy Bitcoin-exposure at a discount Guide on long-term options for strategic portfolio management Assignment explained - 01 - what every options trader and investor should know Assignment explained - 02 - how to avoid assignment Assignment explained - 03 - how to use option assignment to your advantage Assignment explained - 04 - option assignment cheat sheet
More from the author             
  • Koen Hoorelbeke's articles on Saxo
  • Follow and interact with me on the new BlueSky social media platform
This material is marketing content and should not be regarded as investment advice. Trading financial instruments carries risks and historic performance is not a guarantee of future results. The instrument(s) referenced in this content may be issued by a partner, from whom Saxo receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options..
Koen HoorelbekeInvestment and Options StrategistSaxo Bank
Topics: Options Thought Starters Investing with options Highlighted articles Listed Options Palantir Technologies Inc. Palantir Technologies